ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Challenges Use Of Avastin In UK To Treat Eye Disease

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Swiss drug maker Novartis (NVS) is challenging the use of a unlicensed cheaper medicine to treat an eye disease in the U.K. as an alternative to its drug Lucentis. "It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available," Novartis said in a statement. "It undermines the regulatory process that was introduced to safeguard patients." Novartis also said there is "emerging evidence" of potential safety concerns on the use of Avastin, or bevacizumab, to treat a neovascular form of age related macular degeneration, known as wet AMD. The BBC Tuesday said Novartis was seeking a judicial review of the policy to pay for Avastin on the publicly funded National Health Service, after the NHS in four areas in the south of England agreed last year that Avastin could be prescribed for the condition. Novartis declined to comment on whether it was seeking the review. Lucentis, Novartis' best-selling eye drug which generated $2.05 billion in sales in 2011, is recommended for use by the NHS to treat wet age-related macular degeneration. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/10/201412:25:40Zurich Stocks See Gains
04/09/201408:34:24Novartis Names New Alcon, Sandoz Division Heads -- Update
04/09/201402:50:35Novartis Names New Alcon, Sandoz Division Heads
04/03/201417:12:35ADR Shares End Lower; Vodafone Shares Active
04/02/201416:55:18ADR Shares End Higher; Noah Education Shares Active
03/31/201417:16:48ADR Shares End Higher; ING, Novartis Shares Active
03/31/201412:29:09EUROPE MARKETS: European Stocks End Mixed On Inflation Jitters
03/31/201411:07:25Supreme Court to Review Teva Appeal in Copaxone Patent Case
03/31/201410:29:55EUROPE MARKETS: European Stocks Push Higher After Weak Inflation
03/31/201406:22:12EUROPE MARKETS: European Stocks Pare Gains After Weak Inflation...
03/31/201404:55:55EUROPE MARKETS: European Stocks Firm Ahead Of Inflation Data
03/31/201403:25:12Novartis Heart Failure Pill Trial Ends Early on Positive Result
03/26/201413:54:19EUROPE MARKETS: Europe Stocks Higher As ECB Stokes Stimulus Hopes
03/22/201404:16:47Novartis Chairman Stresses Need for R&D Investment
03/21/201413:26:03Glaxo Wins Battle Over Asthma Drug
03/14/201417:12:21ADR Shares End Lower; GlaxoSmithKline Shares Active
03/14/201412:10:09HSBC Taps Symonds as Chairman of European Retail Unit
03/14/201411:55:38HSBC Appoints Former Novartis CFO as Chairman of European Retail...
03/07/201408:12:10EUROPE MARKETS: European Stocks Head For Weekly Loss Ahead Of...
02/26/201412:40:17Novartis to Shut U.K. Plant, Cut 361 Jobs

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad